Cure TV

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.

New findings show that Ibrance has the potential to help patients with brain metastases that harbor a CDK pathway alteration.

At the 2019 MPN Heroes® event Tammy Matuska, B.S.N., RN, known as the "lifeline to patients," was honored for her outstanding work for patients with MPN.

The overall survival rate in patients with melanoma has increased exponentially in the past decade. But thanks to the use of combinations in the treatment of melanoma, the future looks even brighter, according to one expert from the Melanoma Institute Australia.

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

When others assume that patients with lung cancer must have smoked to get the disease, this stigma can affect patient outcomes.

Immunotherapy in combination with chemotherapy is becoming a popular treatment for patients with lung cancer, but patients need to understand the side effects.

An overview of the therapies available for patients with diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma.

While scientists have a limited understanding of how brain metastases genetically evolve from their primary tumor, research presented at the Society for Neuro-Oncology’s Annual Meeting may have identified a connection between genetic mutations and treatment options that could offer patients improved outcomes.

There is plenty of scientific data about the physical challenges patients with cancer endure, but more is needed to address psychosocial issues.

To combat the stigma around mental health care for patients with lung cancer, survivor Nancy Cohen shares her own treatment story and why she feels it's important to include mental health care during cancer treatment.

Hossein Borghaei, DO, MS, of Fox Chase Cancer Center, discusses emerging treatment options for patients with lung cancer.

When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.

When making treatment decisions in breast cancer, patient concerns about how each treatment will affect their daily life — and their disease stage — have an important role to play, according to Dr. Sara Hurvitz.

The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

"Sequential treatment in prostate cancer is really something that’s evolving over time," Dr. Daniel Petrylak said of the study findings presented at the European Society of Medical Oncology Congress 2019.

The addition of novel agents in the prostate cancer treatment landscape could create a shift in the way patients with advanced disease are treated, said Dr. Daniel George.

While it is the responsibility of the clinician to inform their patients of all options available, it is, in turn, vital for them to play a role in selecting the cancer treatment that’s right for them, according to Dr. Sara Hurvitz.

While emerging therapies for mantle cell lymphoma (MCL) continue to shape the treatment landscape, no key standard currently exists, says one expert – particularly for older patients, who benefit most from a treatment approach that has been tailored to fit them and their disease.

The Multiple Myeloma Research Foundation is offering exciting new trials for patients with multiple myeloma – including the COMPASS and My Drug trials.

The legendary broadcast journalist Katie Couric sat down with CURE® to talk about founding the Jay Monahan Center for Gastrointestinal Health in honor of her late husband.

The legendary broadcast journalist Katie Couric opened up about what she wishes she’d known and wishes she could tell her younger self when her husband was first diagnosed with cancer.

During an interview with the “CURE Talks Cancer” podcast, retired NHL referee Kerry Fraser discussed what it is like going through treatment for essential thrombocythemia.

Three-time cancer survivor and “Pink Hulk” one-woman show writer and performer, Valerie David, recalls the day she learned she had non-Hodgkin lymphoma.

The legendary broadcast journalist Katie Couric sat down with CURE® to discuss her advocacy work with Stand Up To Cancer and the “With Love, Me” campaign and why they are so special to her.

Retired NHL referee Kerry Fraser explained how rest and exercise both factor into his “new normal” after receiving a diagnosis of essential thrombocythemia in 2017.

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.